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Background: Nitric oxide (NO) is an approved pulmonary vasodilator for neonates and full term infants up to a dose of 80 ppm. At 100 ppm to
200 ppm, NO has potent antimicrobial activities in vitro and in animal studies which suggest its therapeutic use for infectious diseases in humans.
However, whether inhaled NO is safe at 160 ppm in healthy human adults is unknown. The aim of the phase I study was to assess the safety of
delivery and the physiologic effects of intermittent 160 ppm NO in healthy human adults.
Methods: Ten healthy adult volunteers (5 males, 5 females; 20–62 years) were recruited and inhaled 163.3 ppm (SD: 4.0) NO for 30 min, 5 times
daily, for 5 consecutive days. Lung function and blood levels of methemoglobin, nitrites/nitrates, prothrombin, pro-inﬂammatory cytokines and
chemokines were determined before and during treatment.
Results: All individuals tolerated the NO treatment courses well. No signiﬁcant adverse events occurred and three minor adverse events, not
attributable to NO, were reported. Forced expiratory volume in 1 sec % predicted and other lung function parameters, serum nitrites/nitrates,
prothrombin, pro-inﬂammatory cytokine and chemokine levels did not differ between baseline and day 5, while methemoglobin increased
signiﬁcantly during the study period to a level of 0.9% (SD: 0.08) (pb0.001).
Conclusion: These data suggest that inhalation of 160 ppm NO for 30 min, 5 times daily, for 5 consecutive days, is safe and well tolerated in
healthy individuals.
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In patients with cystic fibrosis (CF), life-threatening chronic
microbial lung infections are the leading cause of morbidity and
mortality [1]. The high prevalence of these infections is linked
to mutations in the epithelial chloride channel, CF transmembrane
conductance regulator (CFTR) which impair various mechanisms⁎ Corresponding author at: Division of Infectious Disease, University of
British Columbia, Rm D433, HP East, Vancouver Hospital, 2733 Heather
Street, Vancouver, BC, Canada V5Z-3J5. Tel.: +1 778 899 0607; fax: +1
604 875 4013.
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doi:10.1016/j.jcf.2012.01.003of innate immunity [2]. Early antibiotic eradication treatment
of CF patients for the most prevalent bacterial pathogen,
Pseudomonas aeruginosa, has considerably increased the life
expectancy in CF [3], however still the vast majority of adult
CF patients suffer from chronic P. aeruginosa lung infections
which are difficult to treat due to biofilm formation and the
development of antibiotic resistant clones [3]. Also among
other species, found in CF airways, antibiotic resistant strains
are present including methicillin-resistant S. aureus (MRSA),
members of the Burkholderia cepacia complex, Haemophilus
influenzae, Stenotrophomonas maltophilia, Achromobacter
xylosoxidans, non-tuberculous mycobacteria (NTM) species
and various strict anaerobic bacteria [4,5]. In the light of a. on behalf of European Cystic Fibrosis Society. All rights reserved.
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the unavailability of vaccines against the major CF pathogens in
the last decade [7], it becomes more and more difficult to prevent
or treat these and other infections with the existing classes of
antimicrobial drugs. Thus, there is an unmet need to develop
alternative treatment strategies for patients with CF and other
patient groups at increased risk for microbial infections. The
use of gaseous nitric oxide (NO) might be such an alternative.
NO is an essential part of the innate defense mechanism of the
human immune system [8,9] which becomes up-regulated by the
inducible NO synthase (iNOS) during various inflammatory
conditions and microbial infections [10]. In chronically inflamed
and infected CF patients, however, exhaled NO levels remain low
[11], a phenomenon which has led to nebulized L-arginine sup-
plementation therapy [12]. Inhalation of L-arginine transiently
improved pulmonary function in CF through NO formation
[12], while the inhalation of NO containing gas in concentrations
of 100 ppb to 40 ppm had no immediate effect on lung function
[13].
At 160–200 ppm, NO has also been shown in vitro, ex vivo
and in animal models [14–20] to exert potent antimicrobial effects
against a broad range of microbes, suggesting its use in appropri-
ate concentrations in CF patients. At present, however, inhalation
of NO as a selective, short acting vasodilator is approved only at
80 ppm for use in full term infants with hypoxic respiratory failure
associated with pulmonary hypertension [21,22]. Thus, higher
antimicrobial doses of NO for treating CF patients requires
phase I safety studies in healthy human individuals.
Potential side effects of high dose NO treatment include the
binding of NO to hemoglobin, forming methemoglobin, which
could lead to decreased oxygen transport and the capacity of
NO to act as a nitrosylating agent on proteins and other cell
constituents [23–25]. Thus, concerns have been raised regarding
the potential use of NO as a microbicidal agent in various clinical
scenarios [26].
Here we report on a prospective phase I open label safety
study in 10 healthy adults, who inhaled 160 ppm gNO for
30 min, five times a day, for 5 consecutive days. Neither signif-
icant adverse events nor adverse events attributable to NO
occurred and all individuals tolerated the NO treatment courses
well. Forced expiratory volume in 1 sec (FEV1) % predicted
and other lung function parameters and serum nitrites/nitrates,
prothrombin, pro-inflammatory cytokine and chemokine levels
did not differ between baseline and day 5, while methemoglobin
levels increased during the study period to a level of 0.9%. We
conclude that inhalation of 160 ppm NO for 30 min, 5 times
daily, for 5 consecutive days, is safe and well tolerated in healthy
individuals.
2. Individuals, materials and methods
2.1. Study design
Ten healthy adult volunteer subjects (5 males, 5 females),
aged 20 to 62 years, were enrolled in the study after screening
their medical history, a physical examination, pulmonary function
tests and blood values. Exclusion criteria included individuals lessthan 19 years of age, pregnant females and unwilling to practice
birth control during the study, diagnosed with pulmonary disease,
epistaxis, hemoptysis, methemoglobinemia, organ transplant re-
cipient or receiving antibiotic therapy. After obtaining informed
consent, treatment was initiated within 5 days of enrollment. Sub-
jects were housed in a hospital ward and received 160 ppm NO
for 30 min every 4 h, five times a day, for 5 consecutive days
by inhalation. Subjects were administered NO through a modified
disposable mouthpiece to maximize mixing. Inspiration was
spontaneously initiated by the subject from a conventional inter-
mittent positive pressure breathing respirator (Mark-7,Carefusion,
USA) in fixed flow mode delivering 48 l per minute (LPM).
Flows of gas were verified with a calibrated mass flow meter
(TSI, USA). Nitric oxide (INOmax, Ikaria, USA) of 800 ppm
nitric oxide at 12 LPM was titrated into a distal delivery port on
the mouth piece connected to the respirator during inspiratory
phase only (pressure switch). The Mark 7 respirator was supplied
by an air/oxygen blender (Bird Sentry, Carefusion, USA) set to
deliver 26% oxygen. Subjects returned for follow-up evaluations
3, 7 and 21 days after the final NO administration. Subject safety
was determined by monitoring vital signs, methemoglobin levels,
lung function, blood chemistry, hematology, prothrombin time,
inflammatory cytokine/chemo-kines levels and endothelial acti-
vation. These parameters were compared to baseline and at vari-
ous timepoints during and after NO administration. The protocol
was approved by the University of British Columbia clinical re-
search ethics board, Vancouver Coastal Health Research Institute
and the Therapeutic Products Directorate of Health Canada (TPD,
CTANumber 129958). In addition, all components of the NO de-
livery systemwere approved by the Therapeutic Product Director-
ate of Health Canada.
2.2. Monitoring of NO, NO2, O2 and methemoglobin levels
The target gas mixture was 160 ppm gNO with a nitrogen
dioxide (NO2) less than 5 ppm and an oxygen (O2) level between
21% and 25%. Inspiratory NO, NO2 and O2 levels were continu-
ously monitored by sampling from the mouthpiece sample port
located about 6 millimeters from the mouth of the subject with
an AeroNOx (Pulmonox, AB, Canada) NO, NO2 and O2 electro-
chemical analyzer. Delivery safety was determined by the num-
ber of occasions that NO2 exceeded 5 ppm, NO exceeding 10%
variation and O2 dropping below 20% during NO treatments. A
commercially available noninvasive pulse oximeter (Rad 57,
MasimoCorporation, USA)was used tomeasure methemoglobin
saturation (SpMet). These parameters were measured continu-
ously during every NO treatment course and for 3.5 h after the
first treatment of the day. Daily serum samples were collected
and frozen at −80 °C and the serum nitrite/nitrite level was mea-
sured using the Griess reagent [27].
2.3. Pulmonary function tests
Subjects had full pulmonary function tests (PFT) performed
including lung diffusing capacity (DLCO) by a trained techni-
cian utilizing a calibrated pulmonary function system (Jaeger
MasterScreen, VIASYS Healthcare, USA) on screening and
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Medical, England) was performed on days 1, 3 and 4. Effect of
NO on lung function and DLCO was determined by changes
between baseline, treatment days and follow up days.
2.4. Oxygenation and vital sign measurements
Full physicals were performed by a pulmonary physician on
screening and on days 8, 12 and 26. Abbreviated physical
examination by a registered nurse was done each day prior to
initiation of treatments on days 1–5. Oxygenation was measured
with a pulse oximeter (Rad 57, Masimo Corporation, USA)
which was used according to manufacturer's guidelines to
measure functional oxygen saturation of arterial hemoglobin
(SpO2) and heart rate. These parameters were measured
continuously during every NO treatment and for 3.5 h after the
first treatment of the day. Cardiovascular status was determined
by monitoring heart rate, blood pressure, respiratory rate and
temperature. Values were recorded prior to the start of each
treatment, following a 5-min rest. During treatments, vital signs
(except temperature) were also performed 15 min after the start
of the treatment and at the end of NO treatment and recorded.
After the first treatment each day, vital signs were recorded at
every 30 min until the start of the second treatment of the day.
2.5. Blood chemistry, hematology and inflammation
measurements
Hematological assessment included a complete blood count
and differential (hemoglobin, hematocrit, red blood cell count,
white blood cell count, white blood cell differential, and platelet
count). The blood chemistry profile included serum creatinine,
and liver function tests: aspartate aminotransferase (AST) serum
glutamic oxaloacetic transaminase (SGOT), alkaline phospha-
tase, and gamma-glutamyl transferase (GGT). The effect of NO
on coagulation was determined by the prothrombin time (PT)
and its derived measures of prothrombin ratio (PR) and interna-
tional normalized ratio (INR). Heparinized plasma was collected
at baseline and on days 1, 2, 4, and 5 of NO treatment, and on
follow-up days 3, 7 and 21 and frozen at −80 °C. Plasma cyto-
kine levels were assessed using the human inflammation cytokine
bead array kit (BD Bioscience, Canada). Plasma levels of angio-
poietin (Ang)-1 and Ang-2 were determined by ELISA (R&D
Systems, USA).
2.6. Statistical analysis
Descriptive characteristics of the subjects prior to, during, and
at the end of the study were tabulated and expressed as mean±
standard deviation (SD). Differences in continuous variables
(methemoglobin, serum nitrate and SpO2 levels) over the course
of the study were analyzed utilizing repeated measures analysis
of variance. Categorical events (number of subjects with a partic-
ular adverse event) were determined by constructing 95% confi-
dence limits for their incidence. Differences between important
continuous variables at two specific times were evaluated with
the paired t-test. Important categorical events such as clinicalpulmonary function and lung diffusion changes, changes in
serum inflammatory markers, hematology, clinical chemistry
and incidence of adverse events were analyzed by constructing
95% confidence limits for their incidence. The data were ana-
lyzed using the unpaired Mann–Whitney test for comparison
between any two groups and ANOVA for repeated measures of
variance. Baseline comparisons were analyzed by repeated
measures ANOVA with Bonferroni post test for parametric
data, or Friedman test with Dunn's post test for non-parametric
data. Data analysis and graphical presentation were done using
a commercial statistics package (Graphpad-Prism V 3.0,
GraphPad Software Inc., USA). Unless otherwise specified,
pb0.05 indicated statistical significance. Results were represented
by mean±SD from at least three independent measurements.
3. Results
3.1. Adverse effects
We investigated the safety to deliver repeatedly a concentra-
tion of 160 ppm NO into airways of 10 healthy adult individ-
uals without unacceptable adverse effects including excessive
NO2 levels, while maintaining acceptable arterial hemoglobin
oxygen saturation (SpO2). A total of 250 NO treatments were
administered to the 10 subjects during the study period. All
treatments were well tolerated and no significant adverse events
were observed. Three minor adverse events were reported: One
subject reported bruising of the arm from multiple attempts to
successfully draw blood, while two other subjects reported a
numbing sensation of the tongue during NO treatment. This
was resolved by instructing the subject to relax and reposition
the mouth piece.
3.2. NO, NO2 and O2 levels
A total of 750 measurements of NO were recorded during
the study. The average inspired NO was 163.3 ppm (SD=4.0).
The highest NO concentration recorded was 177 ppm. The
highest NO2 level recorded during the treatments was 2.8 ppm
(mean: 2.32; 95% confidence level: 2.17–2.47 ppm) and none
of the subjects experienced a NO2 levelN5 ppm. This was
consistent with the performance specifications provided by
the manufacturer of the apparatus of 1.56 ppm (SD=0.3).
Of the 300 recorded oxygen values, the average oxygen %
was 22.0% (SD=0.22).
3.3. Vital signs and clinical safety
During and after the NO exposure, all vital signs remained
within normal limits for age and with respect to baseline values.
Specifically, there was no drop in blood pressure (potentially due
to the vasodilator effect of NO) during or after NO treatments. No
sudden incidences of hypoxemia (b85% SpO2) were observed
during or after NO administration. The lowest observed SpO2
was 93%. SpO2 levels over time decreased slightly between the
pretreatment and post treatment but neither differed significantly
statistically nor clinically. ANOVA analysis ruled out that this
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over the course of the same day. All 930 recordedmethemoglobin
percent levels (SpMet) remained below 5%. The initial baseline
SpMet was 0.16% (SD=0.10). The highest SpMet was observed
at the end of the 30 min treatment and was 2.5% with an average
increase of 0.9% (SD=0.08). SpMet increased as predicted by
~1% between pretreatment and post treatment (pb0.001) and
returned to baseline after 3.5 h prior to the next NO treatment
(Fig. 1A). ANOVA analysis ruled out that this increase was
associated with repeated treatments on the same day. There was
no accumulative effect on SpMet after five daily treatments for
5 consecutive days (Fig. 1B). Follow-up SpMet measurements
on 3, 7 and 21 days after the final NO exposure on day 5 did
not demonstrate any residual increase in SpMet. Methemoglobin
is reduced by an enzymatic reductase resulting theoretically in an
increase in blood nitrite/nitrate levels. However, no significant
differences in serum nitrite/nitrate levels from baseline were
observed during the trial. One subject had significantly higher
peak nitrite and nitrate values (pb0.001) which was also slightly
different at baseline (p=0.038) compared to the other subjects.
There were no statistically, nor clinically significant changes
in blood coagulation parameters, clinical chemistry and hemato-
logical parameters from baseline to completion of day 5. Although
eosinophil cell numbers decreased during the study (baseline 0.15
giga/L; SD=0.12; end of study: 0.19 giga/L (SD=0.19), this
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Fig. 1. Methemoglobin levels (%) before, during and after inhalation of
160 ppm nitric oxide in healthy human individuals. The 10 individuals
performed 5 NO treatment courses daily, lasting 30 min each, for 5 consecutive
days. Methemoglobin levels were measured using a pulse oximeter. A, Values
represent pooled values of 250 individual 30 min NO treatment courses from 10
subjects and pooled values obtained at 120 min, 180 min and 240 min after NO
treatment was discontinued. B, Values represent pooled values of 10 individuals
at the beginning and end of 30 min NO treatment courses and pooled values
obtained 8, 12 and 26 days after NO treatment was discontinued.neutrophil cell numbers from a baseline value of zero to 0.01
giga/L at the end of study was found, which also did not reach
statistical nor clinical significance (p=0.169).3.4. Pulmonary function, inflammatory cytokines and endothelial
activation factors
Pulmonary function tests did not reveal any abnormalities
for any subjects during and after NO treatments. Specifically,
airflow as measured by FEV1 and maximum mid-expiratory
flow (MMEF) did not differ from baseline during the course
of the study. Other lung function measurements such as
DLCO, forced vital capacity (FVC), total lung capacity (TLC)
and residual volume (RV) also did not change from baseline
measurement (Fig. 2).
To assess whether NO treatment resulted in inflammation or
endothelial activation we quantified cytokines and the vascular
endothelium activation factors Ang-1 and Ang-2 in peripheral
plasma at baseline and various time points thereafter. Cytokine
levels of TNF, IL-6, IL-8, IL-10, IL-1b and IL-12p70 were
unaffected by inhalation of NO as compared to baseline.
Comparisons between baseline cytokine levels and levels at
each of the sampling time points for all 10 participants
resulted in no significant differences (compared by repeated
measures ANOVA with Bonferroni post test for parametric
data, or Friedman test with Dunn's post test for non-parametric
data (Fig. 3). Furthermore, Ang-2 and Ang-2/Ang-1 ratios were
not affected in this study (Fig. 4). Outlier data in Fig. 4 did not
show any correlation with changes in any of the other parameters,
and thus appears to be an isolated finding of unknown
significance.4. Discussion
Here we provide evidence that 160 ppm NO, a concentration
previously identified as an effective antimicrobial dose against
various microorganisms in vitro, ex vivo and in animal models
[16,17,19], can be safely delivered to healthy human lungs in a
pulsed manner for 5 consecutive days. No significant adverse
events occurred and only three minor adverse events, not
attributable to NO, were reported. Furthermore all vital
signs remained well within acceptable clinical margins.
Our findings are similar and even slightly better compared to
continuous inhalation of 80 ppm NO—the approved NO dose
for inhalational use in full term infants—with regards to methe-
moglobin and NO2 levels, most likely due to the intermittent
dosing strategy utilized here. While in our study all 930
recorded SpMet levels remained below 5%, continuous deliv-
ery of 80 ppm NO was reported to rise to at least 5% with
35% of the subjects exceeding 7% [28]. Formation of methe-
moglobin has been also observed in previous studies of NO in-
halation by healthy human individuals [23–25]. NO was
inhaled for 3 h up to 128 ppm and 55 min at 512 ppm before
methemoglobin reached 5% [25]. The rise in methemoglobin
and its decay after cessation of NO inhalation in that study fol-
lowed a first order pharmacokinetics model and clearance time-
Fig. 2. Pulmonary function before, during and after inhalation of 160 ppm nitric oxide in healthy human individuals. Baseline values of pulmonary function tests were
obtained within 7 days prior to NO therapy. Values during NO treatment were obtained on day 2. Further values were determined after the final NO treatment on day
5 and on days 8, 12 and 26. FEV1: forced expiratory volume in 1 second; MMEF: maximum mid-expiratory flow; DLCO: carbon monoxide diffusing capacity; FVC:
forced vital capacity TLC: total lung capacity; RV: residual volume. Data are presented as means of all ten subjects and absolute differences compared to baseline
prior to NO treatment. Statistical differences were assessed by Mann–Whitney test.
328 C. Miller et al. / Journal of Cystic Fibrosis 11 (2012) 324–331constants lay between 39 and 91 min. The predicted half-life of
methemoglobin in humans is approximately 1 h.
We hypothesized that administering high dose NO for 30 min
followed by a 3.5 h break would allow methemoglobin levels to
return to baseline between treatment courses [19]. The anticipated
rise inmethemoglobin during one treatment coursewas calculated
to be 1%. The actual average rise in methemoglobin percent for
the ten individuals for a single treatment course was consistent
with these kinetic estimates at 0.9% considering the ±1% absolute
accuracy of the pulse oximeter. Our study also confirmed that the
predicted 3.5 h interim period allowed the methemoglobin con-
centration to return to baseline, allowing five cycles daily for
5 days without a significant clinical increase in methemoglobin
concentrations. Taken together, we have shown that our intermit-
tent NO dosing strategy is safe with regard of methemoglobin
production and metabolic burden.
Similar to methemoglobin levels, also the mean peak concen-
trations of NO2 level in our study (2.8 ppm) was comparable with
that observed during continuous delivery of 80 ppm (2.6 ppm)[28]. The limitations of this and other studies with regard to NO
delivery are that the NO and NO2 levels are only known at the
entry point into the subjects' respiratory tract and the actual
resulting levels of oxides of nitrogen in the lung are unknown.
To date, studies indicate that acute pulmonary injury, pulmonary
edema, hemorrhage, changes in surface tension of surfactant,
reduced alveolar numbers and airway responsiveness may be
caused by high airway levels of NO, NO2 and other oxides
of nitrogen [26]. It has been reported that human cells have sig-
nificantly elevated thiol levels and can cope with high concen-
trations of NO better than prokaryotes [29]. We have reported
that the same concentration level of NO that is cidal to microbes
may be tolerated by the host cells [30]. This may not be surpris-
ing, considering that the body's innate defense mechanism relies
on NO released frommacrophage and neutrophils to act as one of
the key non-specific antimicrobial agents [9,10]. Despite this
resilience to nitrosative stress, it may well be prudent in future
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Fig. 3. Cytokine blood levels before and after inhalation of 160 ppm nitric oxide in healthy human individuals. Blood was collected within 7 days prior to NO therapy.
Further blood samples were taken each day during NO treatment and on days 8, 12 and 26. Plasma levels of tumour necrosis factor (TNF)α, interleukin (IL)-1ß, IL-6,
IL-8, IL-10 and IL-12p70 were determined by a cytometric bead array. Statistical differences were compared by repeated measures ANOVA with Bonferroni post test
for parametric data (IL-6, IL-8, IL-10, IL-12p70), or Friedman test with Dunn's post test for non-parametric data (TNF and IL-1b).
329C. Miller et al. / Journal of Cystic Fibrosis 11 (2012) 324–331Our study also demonstrates that 160 ppm NO, delivered as
outlined, minimally impacts lung function. Specifically, acute
airway inflammation, measured by determining flow rates, was
not detectable. Possibly, potential deleterious airway reactivity
could be masked by the ameliorative smooth muscle relaxation
that can be exerted by NO [31]. In patients with pulmonary
infection, high NO delivery might cause an increase in airway
reactivity. However, the vasodilatory activity of NO may benefit
the patient in addition to the antimicrobial activity of NO. The
delivery of 160 ppm NO did not cause lung parenchymal injury,
as measured by different lung function parameters. Likewise,
plasma inflammatory cytokine levels, the earliest host responses
to lung injury [32] and levels of eosinophils and neutrophils
remained constant. In addition, the vascular endothelial activation
factors Ang-1, -2 and the Ang-2/Ang-1 ratio [33,34] were unaf-
fected by the NO treatment courses in our study.
Importantly, pulmonary function mechanics and inflamma-
tory markers remained unchanged compared to baseline valuesin measurements 3 days and 28 days post treatment. While we
cannot exclude the possibility that some longer term change
may occur in lung function, the absence of any sign of inflam-
mation in the post treatment period makes this unlikely. Serum
inflammatory markers may possibly have not been sensitive
enough to measure acute or even chronic changes in the lungs.
Ideally, inflammatory markers from bronchoalveolar lavage
(BAL) fluids would have been sampled but in our study it was
not deemed ethical to perform BAL in the healthy volunteers
enrolled.
The present results are the prerequisite for further NO inha-
lation studies in patients with lung infections such as patients
with CF or COPD. For such studies, the currently approved
dose of 80 ppm NO is presumably too low to exert bactericidal
effects as shown by previous studies [35–37]. On the contrary,
studies in animals reveal that 160 ppm NO is effective to reduce
the pulmonary bioburden and leukocyte infiltration in a rat
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Fig. 4. Plasma levels of angiopoietin (Ang)-1 and Ang-2 before and after
inhalation of 160 ppm nitric oxide in healthy human individuals. Blood was
collected within 7 days prior to NO therapy. Further blood samples were
taken each day during NO treatment and on days 8, 12 and 26. Plasma levels
of Ang-1, Ang-2, and Ang-2/Ang-1 ratios were determined using a cytometric
bead array. Statistical differences were assessed compared by Friedman test with
Dunn's post test.
330 C. Miller et al. / Journal of Cystic Fibrosis 11 (2012) 324–331decrease the clinical symptoms of bovine respiratory disease in
cattle [39]. Whether even doses higher than 160 ppm NO are
needed to be bactericidal in atelectatic or consolidated areas
of the lung in CF patients, has to be shown in further studies.
Acknowledgments
The authors wish to acknowledge Alex Stenzler of 12th Man
Technologies, Inc. and Bruce Murray of Nitric Solutions for
their expertise in devices and overall technical guidance. We
wish to thank Tom Bachman for his guidance with statistical
analysis. This study was funded by the Lotte and John Hecht
Foundation. We would like to thank CareFusion for supplying
equipment and partial funding. Ikaria provided the nitric
oxide gas support of this study.References
[1] Hodson ME, Geddes D, Bush A, editors. Cystic Fibrosis. 3rd ed. London:
Hodder Arnold; 2007.
[2] Doring G, Hoiby N. Consensus Study Group. Early intervention and
prevention of lung disease in cystic fibrosis: a European consensus. J Cyst
Fibros 2004;3:67–91.
[3] Döring G, Gulbins E. Cystic fibrosis and innate immunity: how chloride
channel mutations provoke lung disease. Cell Microbiol 2009;11:208–16.
[4] Cystic Fibrosis Trust. Antibiotic treatment for cystic fibrosis - report of the
UK cystic fibrosis antibiotic working group; 2009.
[5] Tunney MM, Field TR, Moriarty TF, Doering G, Muhlebach MS, Wolfgang
MC, et al. Detection of anaerobic bacteria in high numbers in sputum from pa-
tients with cystic fibrosis. Am J Respir Crit Care Med 2008;177:995–1001.
[6] Walsh C. Where will new antibiotics come from? Nat Rev Microbiol
2003;1:65–70.
[7] Döring G, Meisner C, Stern M, for the Flagella Vaccine Trial Study
Group. A double-blind randomized placebo-controlled phase III study of
a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients.
PNAS 2007;104:11020–5.
[8] Liew FY, Cox FE. Nonspecific defence mechanism: the role of nitric
oxide. Immunol Today 1991;12:A17–21.
[9] Fang FC. Antimicrobial reactive oxygen and nitrogen species: concepts
and controversies. Nat Rev Microbiol 2004;2:820–32.
[10] MacMicking J, Xie QW, Nathan C. Nitric oxide and macrophage function.
Annu Rev Immunol 1997;15:323–50.
[11] Meng Q-H, Springall DR, Bishop AE, Morgan K, Evans TJ, Habib S,
et al. Lack of inducible nitric oxide synthase in bronchial epithelium: a
possible mechanism of susceptibility to infection in cystic fibrosis. J
Pathol 1998;184:323–31.
[12] Grasemann H, Kurtz F, Ratjen F. Inhaled L-arginine improves exhaled
nitric oxide and pulmonary function in patients with cystic fibrosis. Am
J Respir Crit Care Med 2006;174:208–12.
[13] Ratjen F, Gartig S, Wiesemann HG, Grasemann H. Effect of inhaled nitric
oxide on pulmonary function in cystic fibrosis. RespirMed 1999;93:579–83.
[14] Kelly TJ, DrummML. Inducible nitric oxide synthase expression is reduced
in cystic fibrosis murine and human airway epithelial cells. J Clin Invest
1998;102:1200–7.
[15] McMullin B, Chittock D, Roscoe D, Garcha H, Wang L, Miller C. The
antimicrobial effect of nitric oxide on the bacteria that cause nosocomial
pneumonia in mechanically ventilated subjects in the ICU. Respir Care
2005;50:1451–6.
[16] Ghaffari A, Neil DH, Ardakani A, Road J, Ghahary A, Miller CC. A direct
nitric oxide gas delivery system for bacterial and mammalian cell cultures.
Nitric Oxide 2005;12:129–40.
[17] Ghaffari A, Jalili R, Ghaffari M, Miller C, Ghahary A. Efficacy of gaseous
nitric oxide in the treatment of skin and soft tissue infections. Wound Repair
Regen 2007;15:368–77.
[18] Miller CC, Miller MK, Ghaffari A, Kunimoto B. The treatment of chronic
non-healing leg ulceration with gaseous nitric oxide – a case study. J Cutan
Med Surg 2004;8:233–8.
[19] Miller CC, McMullin B, Ghaffari A, Stenzler A, Pick N, Roscoe D, et al.
Gaseous nitric oxide bactericidal activity retained during intermittent high-
dose short duration exposure. Nitric Oxide 2009;20:16–23.
[20] Stenzler A, Miller C. Device and method for treatment of wounds with
nitric oxide. US Patent 7520866.
[21] Food and Drug Administration. Approval of NDA 20–846 INOmax nitric
oxide gas; 1999.
[22] Guidance for industry and for FDA reviewers - guidance document for
premarket notification submissions for nitric oxide delivery apparatus,
nitric oxide analyzer and nitrogen dioxide analyzer; Jan. 24 2000.
[23] Borgese N, Pietrini G, Gaetani S. Concentration of NADH-cytochrome b5 re-
ductase in erythrocytes of normal and methemoglobinemic subjects measured
with quantitative radioimmunoblotting assay. J Clin Invest 1987;80:1296–302.
[24] Young JD, Dyar O, Xiong L, Hoell S. Methaemoglobin production in
normal adults inhaling low concentrations of nitric oxide. Intensive Care
Med 1994;20:581–4.
331C. Miller et al. / Journal of Cystic Fibrosis 11 (2012) 324–331[25] Young JD, Sear JW, Valvini EM. Kinetics of methaemoglobin and serum
nitrogen oxide production during inhalation of nitric oxide in volunteers.
Br J Anaesth 1996;76:652–6.
[26] Hurford W. Nitric oxide as a bactericidal agent: is the cure worse than the
disease? Respir Care 2005;50:1428–9.
[27] Green LC,Wagner DA, Glogowski J, Skipper PL,Wishnok JS, Tannenbaum
SR. Analysis of nitrate, nitrite, and [15N] nitrate in biological fluids. Anal
Biochem 1982;126:131–8.
[28] INOmax (nitric oxide) for inhalation. Prescribing information. http://
inomax.com/assets/pdf/INOmax-PI-web-0909.pdf.
[29] Meister A. Glutathione metabolism and its selective modification. J Biol
Chem 1988;263:17205–8.
[30] Miller CC, Rawat M, Johnson T, Av-Gay Y. Innate protection of
Mycobacterium smegmatis against the antimicrobial activity of nitric
oxide is provided by mycothiol. Antimicrob Agents Chemother 2007;51:
3364–6.
[31] Dupuy PM, Shore SA, Drazen JM, Frostell C, Hill WA, Zapol WM.
Bronchodilator action of inhaled nitric oxide in guinea pigs. J Clin Invest
1992;90:421–8.
[32] O'Shea JJ. Jaks, STATs, cytokine signal transduction, and immunoregulation:
are we there yet? Immunity 1997;7:1–11.
[33] Conroy AL, Phiri H, Hawkes M, Glover S, Mallewa M, Seydel KB, et al.
Endothelium-based biomarkers are associated with cerebral malaria in Mal-
wian children: a retrospective case-control study. PLoS One 2010;5:e15291.[34] Ricciuto DR, Dos Santos CC, Hawkes M, Toltl LJ, Conroy AL, Rajwans
N, et al. Angiopoietin-1 and angiopoietin-2 as clinically informative prog-
nostic biomarkers of morbidity and mortality in severe sepsis. Crit Care
Med 2011;39:702–10.
[35] Webert KE, Vanderzwan J, Duggan M, Scott JA, McCormack DG, Lewis
JF, et al. Effects of inhaled nitric oxide in a rat model of Pseudomonas
aeruginosa pneumonia. Crit Care Med 2000;28:2397–405.
[36] Jean D, Maitre B, Tankovic J, Meignan M, Adnot S, Brun-Buisson C,
et al. Beneficial effects of nitric oxide inhalation on pulmonary bacte-
rial clearance. Crit Care Med 2002;30:442–7.
[37] Long R, Talbot J, Mayers RL, Jones RL. Treatment of sputum-smear positive
pulmonary tuberculosis with inhaled nitric oxide. Antimicrob Agents
Chemother 2005;49:1209–12.
[38] Hergott CA, Rohan M, Farley K, McCormack DG, Mehta S. Effects of
continuous vs pulsed inhaled nitric oxide in a rat model of Pseudomonas
aeruginosa pneumonia. Am J Respir Crit Care Med 2006;173:A135.
[39] Schaefer AL, Perry BJ, Cook NJ, Miller C, Church J, Tong AKW, et al.
Infrared detection and nitric oxide treatment of bovine respiratory disease
(BRD). Online J Vet Res 2006;10:7–16.
